Mutagenic evaluation of combined paclitaxel and cisplatin treatment in somatic cells of Drosophila melanogaster

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 696, Issue 2, 2010, Pages 139-143

  Danesi, Cristiane Cademartori ^a,b   Bellagamba, Bruno Corrêa ^a   Dihl, Rafael Rodrigues ^a   de Andrade, Heloísa Helena Rodrigues ^a   Cunha, Kênya Silva ^c   Spanó, Mário Antônio ^d   Reguly, Maria Luíza ^a   Lehmann, Mauricio ^a  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^d FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

Cisplatin; Drosophila melanogaster; Genotoxicity; Head and neck cancer; Paclitaxel; SMART

Indexed keywords

CISPLATIN; PACLITAXEL; PLATISTINE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA DAMAGE; DROSOPHILA MELANOGASTER; FEMALE; GENE FREQUENCY; GENOTOXICITY; GENOTYPE; HETEROZYGOTE; MALE; MITOTIC RECOMBINATION; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; SOMATIC CELL; SOMATIC MUTATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DNA DAMAGE; DROSOPHILA MELANOGASTER; LOSS OF HETEROZYGOSITY; MUTAGENICITY TESTS; MUTAGENS; PACLITAXEL;

DROSOPHILA MELANOGASTER;

EID: 77249103954     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2010.01.002     Document Type: Article

References (44)

1. Argiris A., Karamouzis M.V., Raben D., and Ferris R.L. Head and neck cancer. Lancet 371 (2008) 1695-1709
2. Cruz J.J., Ocaña A., Navarro M., Barco E.D., and Fonseca E. New options in the treatment of locally advanced head and neck cancer: role for induction chemotherapy. Cancer Treat. Rev. 34 (2008) 268-274
3. Hitt R., Ciruelos E., Amador M.L., Benito A., Sanchez J.J., Ballestin C., and Cortes-Funes H. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur. J. Cancer 41 (2005) 453-460
4. Yao M., Epstein J.B., Modi B.J., Pytynia K.B., Mundt A.J., and Feldman L.E. Current surgical treatment of squamous cell carcinoma of the head and neck. Oral Oncol. 43 (2007) 213-223
5. Herchenhorn D., and Dias F.L. Advances in radiochemotherapy in the treatment of head and neck cancer. Rev. Hosp. Clin. Fac. Med. Sao Paulo 59 (2004) 39-46
6. Haddad R., Annino D., and Tishler R.B. Multidisciplinary approach to cancer treatment: focus on head and neck cancer. Dent. Clin. North Am. 52 (2008) 1-17
7. Lee K.C., Lee S.H., Lee Y., Park S.H., Park J., Cho E.K., Shin D.B., Lee J.H., Kim D.Y., and Kim S.T. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 71 (2008) 187-191
8. Lung T., Tǎşcǎu O.C., Almǎşan H.A., and Mureşan O. Head and neck cancer, treatment, evolution and post therapeutic survival. Part 2. A decade's results 1993-2002. J. Craniomaxillofac. Surg. 35 (2007) 126-131
9. Agada F.O., Alhamarneh O., Stafford N.D., and Greenman J. Immunotherapy in head and neck cancer: current practice and future possibilities. J. Laryngol. Otol. 123 (2009) 19-28
10. Ayllón Barbellido S., Campo Trapero J., Cano Sánchez J., Perea García M.A., Escudero Castaño N., and Bascones Martínez A. Gene therapy in the management of oral cancer: review of the literature. Med. Oral Patol. Oral Cir. Bucal 13 (2008) E15-E21
11. Corti L., Toniolo L., Boso C., Colaut F., Fiore D., Muzzio P.C., Koukourakis M.I., Mazzarotto R., Pignataro M., Loreggian L., and Sotti G. Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma. Lasers Surg. Med. 39 (2007) 394-402
12. Kies M.S. Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN). Curr. Treat. Options Oncol. 8 (2007) 252-260
13. Adamo V., Ferraro G., Pergolizzi S., Sergi C., Laudani A., Settineri N., Alafaci E., Scimone A., Spano F., and Spitaleri G. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol. 40 (2004) 525-531
14. Zhang J., and Tuckett R.P. Comparison of paclitaxel and cisplatin effects on the slowly adapting type I mechanoreceptor. Brain Res. 1214 (2008) 50-57
15. Specenier P.M., and Vermorken J.B. Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol. 45 (2009) 409-415
16. García Sar D., Montes-Bayón M., Aguado Ortiz L., Blanco-González E., Sierra L.M., and Sanz-Medel A. In vivo detection of DNA adducts induced by cisplatin using capillary HPLC-ICP-MS and their correlation with genotoxic damage in Drosophila melanogaster. Anal. Bioanal. Chem. 390 (2008) 37-44
17. Bhana S., Hewer A., Phillips D.H., and Lloyd D.R. p53-dependent global nucleotide excision repair of cisplatin-induced intrastrand cross links in human cells. Mutagenesis 23 (2008) 131-136
18. Langer C.J., Duffy K., Horwitz E.M., Litwin S., Rosvold E., Schol J., Keenan E., Nicolaou N., Friedman C.D., and Ridge J.A. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy. Cancer Invest. 24 (2006) 164-173
19. Sánchez-Suárez P., Ostrosky-Wegman P., Gallegos-Hernández F., Peñarroja-Flores R., Toledo-García J., Bravo J.L., Del Castillo E.R., and Benítez-Bribiesca L. DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer. Mutat. Res. 640 (2008) 8-15
20. Joshi M.C. Cytotoxic drug: towards safer chemotherapy practices. Indian J. Cancer 44 (2007) 31-35
21. Bhatia S., and Sklar C. Second cancers in survivors of childhood cancer. Nat. Rev. Cancer 2 (2002) 124-132
22. Fischer D.J., and Epstein J.B. Management of patients who have undergone head and neck cancer therapy. Dent. Clin. North Am. 52 (2008) 39-60
23. Mayne S.T., and Cartmel B. Chemoprevention of second cancers. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 2033-2037
24. Hsu Y.B., Chang S.Y., Lan M.C., Huang J.L., Tai S.K., and Chu P.Y. Second primary malignancies in squamous cell carcinomas of the tongue and larynx: an analysis of incidence, pattern, and outcome. J. Chin. Med. Assoc. 71 (2008) 86-91
25. Vaamonde P., Martín C., del Río M., and LaBella T. Second primary malignancies in patients with cancer of the head and neck. Otolaryngol. Head Neck Surg. 129 (2003) 65-70
26. Graf U., Würgler F.E., Katz A.J., Frei H., Juon H., Hall C.B., and Kale P.G. Somatic mutation and recombination test in Drosophila melanogaster. Mutat. Res. 271 (1984) 59-67
27. Graf U., Kägi A., Katz A.J., and Würgler F.E. Thirty compounds in the Drosophila wing spot test. Mutat. Res. 222 (1989) 359-373
28. Vogel E.W., Barbin A., Nivard M.J.M., Snack H.F., Waters M.D., and Lohman P.H.M. Heritable and cancer risks of exposures to anticancer drugs: inter-species comparisons of covalent deoxyribonucleic acid-binding agents. Mutat. Res. 400 (1998) 509-540
29. Lindsley D.L., and Zimm G.G. The Genome of Drosophila melanogaster (1992), Academic Press, New York
30. Ramel B., and Magnusson J. Modulation of genotoxicity in Drosophila. Mutat. Res. 267 (1992) 221-227
31. Frei H., and Würgler F.E. Induction of somatic mutation and recombination by four inhibitors of eukaryotic topoisomerases assayed in the wing spot test of Drosophila melanogaster. Mutagenesis 11 (1996) 315-325
32. Frei H., and Würgler F.E. Statistical methods to decide whether mutagenicity test data from Drosophila assays indicate a positive, negative or inconclusive result. Mutat. Res. 203 (1988) 97-308
33. Frei H., and Würgler F.E. Optimal experimental design and sample size for the statistical evaluation of data from somatic mutation and recombination tests (SMART) in Drosophila. Mutat. Res. 334 (1995) 247-258
34. Frei H.-J., Clements J., Hove D., and Würgler F.E. The genotoxicty of the anticancer drug mitoxantrone in somatic and germ-cells of Drosophila melanogaster. Mutat. Res. 279 (1992) 21-33
35. Katz A.J. Genotoxic effects of cisplatin in somatic tissue of Drosophila melanogaster. Environ. Mol. Mutagen. 10 (1987) 197-203
36. Katz A.J. Modulation by temperature of the genotoxic potency of cisplatin in Drosophila wing spot assay. Teratog. Carcinog. Mutagen. 18 (1998) 93-100
37. Cunha K.S., Reguly M.L., Graf U., and de Andrade H.H. Taxanes: the genetic toxicity of paclitaxel and docetaxel in somatic cells of Drosophila melanogaster. Mutagenesis 16 (2001) 79-84
38. Niedernhofer L.J., Lalai A.S., and Hoeijmakers J.H.J. Fanconi anemia (cross)linked to DNA repair. Cell 123 (2005) 1191-1198
39. Gupta Jr. M.L., Bode C.J., Georg G.I., and Himes R.H. Understanding tubulin-Taxol interactions: mutations that impart Taxol binding to yeast tubulin. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 6394-6397
40. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4 (2004) 253-265
41. Digue L., Orsière T., De Méo M., Mattéi M.G., Depetris D., Duffaud F., Favre R., and Botta A. Evaluation of the genotoxic activity of paclitaxel by the in vitro micronucleus test in combination with fluorescent in situ hybridization of a DNA centromeric probe and the alkaline single cell gel electrophoresis technique (comet assay) in human T-lymphocytes. Environ. Mol. Mutagen. 34 (1999) 269-278
42. Lee M., Kwon J., and Chung M.K. Enhanced prediction of potential rodent carcinogenicity by utilizing comet assay and apoptotic assay in combination. Mutat. Res. 541 (2003) 9-19
43. Rodríguez-Arnaiz R., Sortibrán A.C., and Téllez G.O. Detection of mitotic recombination and sex chromosome loss induced by adriamycin, chlorambucil, demecolcine, paclitaxel and vinblastine in somatic cells of Drosophila melanogaster in vivo. Mutagenesis 19 (2004) 121-127
44. Tiburi M., Reguly M.L., Schwartsmann G., Cunha K.S., Lehmann M., and de Andrade H.H.R. Comparative genotoxic effect of vincristine, vinblastine, and vinorelbine in somatic cells of Drosophila melanogaster. Mutat. Res. 519 (2002) 141-149